Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
PLRX vs CAMP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PLRX Captures Overall Composite Edge (39.0 SELL vs 43.9 HOLD), While CAMP Leads 3–2 on Growth & Valuation Pillars
PLRX Overall Winner
6-Pillar Tally: PLRX 2 – 3 CAMP (1 Tie)
Matrix Metrics: PLRX 3 – 4 CAMP
As of Nov 17, 2026, Pliant Therapeutics, Inc. (PLRX) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (39.0/100 SELL vs. 43.9/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality, Options & Positioning), while CAMP wins 3–2 across the 6-pillar growth and valuation breakdown. PLRX trades at $0.66 (N/M Forward P/E, 0.0% operating margin) versus CAMP at $4.00 (N/M Forward P/E, -991.8% operating margin).
- Composite vs. Pillar Nuance: While CAMP currently prints a higher short-term Unified Composite Score (43.9/100 HOLD vs. PLRX 39.0/100 SELL), PLRX captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -991.8% operating margin) and revenue trajectory (-100.0% vs. +138.9% YoY).
- Technical & Structure Timing Caution: PLRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 19.7); meanwhile CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About PLRX vs CAMP
PLRX
Head-to-Head Winner
Pliant Therapeutics, Inc. Common Stock
$0.66
-5.16% 1D
Market Cap
$43.2M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
0.93β · 37% Vol
Unified Composite Score
39.0
SELL
Tech 25.0
Fund 43.0
Flow 63.0
Mom 44.0
Weinstein Technical Phase
Markdown · Sell / avoid
CAMP
CAMP4 Therapeutics Corporation Common Stock
$4.00
+3.63% 1D
Market Cap
$238.5M
TTM Revenue
$5.3M
Forward P/E
N/M
Beta / 30D Vol
1.35β · 94% Vol
Unified Composite Score
43.9
HOLD
Tech 34.0
Fund 40.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (PLRX 2 – 3 CAMP)
1. Valuation Multiples
CAMP
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
26.6x
2. Growth & Scale
CAMP
Revenue Growth (YoY)
-100.0%
+138.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$5.3M
Market Cap
$43.2M
$238.5M
3. Profitability & Quality
PLRX
Gross Margin
N/A
N/A
Operating Margin
0.0%
-991.8%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-50.3%
-146.1%
4. Balance Sheet & Cash Flow
CAMP
Cash Generation (TTM)
-$71M
-$26M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$3.9M Net Debt (0.20x D/E)
$97M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
PLRX
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
12.8% (4th %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: PLRX (3) vs CAMP (4)| Institutional Metric | PLRX | CAMP | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $43.2M | $238.5M | CAMP | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -100.0% | +138.9% | CAMP | |
| Operating Margin (TTM) | 0.0% | -991.8% | PLRX | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -50.3% | -146.1% | PLRX | |
| 52-Week Range Position | 0% ($1–$2) | 23% ($3–$8) | CAMP | |
| Beta / 30D Volatility | 0.93β · 37% Vol | 1.35β · 94% Vol | PLRX | |
| Unified Institutional Score | 39.0 / 100 (SELL) | 43.9 / 100 (HOLD) | CAMP | |
| Trailing 12M Revenue (USD) | N/A | $5.3M | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 26.6x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$71M ($3.9M Net Debt (0.20x D/E)) | -$26M ($97M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CAMP +54.24 pp
3M Horizon
CAMP +29.83 pp
6M Horizon
CAMP +39.22 pp
1Y Horizon
CAMP +58.43 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PLRX Revenue | CAMP Revenue | PLRX Op. Margin | CAMP Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $60M | N/A | -2.2% | N/A | PLRX |
| FY2020 | $40M | N/A | -99.6% | N/A | PLRX |
| FY2021 | $10M | N/A | -1288.1% | N/A | PLRX |
| FY2022 | $10M | N/A | -1313.4% | N/A | PLRX |
| FY2023 | $0M | $0M | -11654.7% | -14822.6% | PLRX |
| FY2024 | N/A | $0M | N/A | -8142.3% | CAMP |
| FY2025 | N/A | $0M | N/A | -1502.4% | CAMP |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
PLRX
UNCLASSIFIED
Current IV
12.8%
IV Percentile
4th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact PLRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CAMP
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
PLRX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CAMP Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ PLRX vs CAMP Key Questions & Quantitative Answers
As of Nov 17, 2026, Pliant Therapeutics, Inc. (PLRX) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (39.0/100 SELL vs. 43.9/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality, Options & Positioning), while CAMP wins 3–2 across the 6-pillar growth and valuation breakdown. PLRX trades at $0.66 (N/M Forward P/E, 0.0% operating margin) versus CAMP at $4.00 (N/M Forward P/E, -991.8% operating margin). Composite vs. Pillar Nuance: While CAMP currently prints a higher short-term Unified Composite Score (43.9/100 HOLD vs. PLRX 39.0/100 SELL), PLRX captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -991.8% operating margin) and revenue trajectory (-100.0% vs. +138.9% YoY). Technical & Structure Timing Caution: PLRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 19.7); meanwhile CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CAMP leads the Growth & Scale pillar: PLRX posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CAMP at +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), PLRX cumulative revenue shifted -83.3% while CAMP shifted N/A. In operating R&D and SG&A reinvestment, PLRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAMP.
CAMP screens cheaper on headline valuation multiples. PLRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PLRX (-50.3% ROE) versus CAMP (-146.1% ROE) capital efficiency.
In options market volatility and institutional positioning, PLRX carries 12.8% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.93β · 37% Vol realized risk). By comparison, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.35β · 94% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CAMP vs PLRX · Reverse Pair
PLRX vs PASG
· Sector Peer
PLRX vs ORIC
· Sector Peer
PLRX vs STOK
· Sector Peer
CAMP vs HLIT
· Sector Peer
CAMP vs ADTN
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem